

DAFTAR PUSTAKA

- Berkshire Priorities Committee. 2002. Policy Statement Sibutramine (Brand Name Reductil). <http://www.nice.nhs.uk>
- Bray, George A., 1998. Obesity. *Harrison's Principles of Internal Medicine*. USA. McGraw-Hill Companies, Inc.
- Chen, C. 1997. *Epidemiology of Obesity In The Asia Pasific Region*. Dalam: *The Asia-Pasific Perspective: Redefining Obesity and It's Treatment*.
- Committee for Proprietary Medicinal Products. *Opinion Following an Article 31 Referral Sibutramine*. Emea (The European Agency for the Evaluation of Medical Products Post-authorisation Evaluation of Medicine for Human Use). 2002. <http://www.emea.eu.int>
- Inoue S., and Zimmet P. 2000. *The Asia-Pasific Perspective: Redefining Obesity and It's Treatment*.
- Ismail *et al.* 1995. *Epidemiology of Obesity In The Asia Pacific Region*. Dalam: *The Asia-Pasific Perspective: Redefining Obesity and It's Treatment*.
- Linggapa. 1997. *Obesity*. IMR Obesity Review. UK. Garrow.
- PT. Abbott Indonesia. *Reductil[®] (Sibutramine hydrochloride monohydrate)*. Brosur produk.
- Sims, Jeremy. *Xenical and Reductil – How They Work*. The Obesity Awareness and Solution Trust. 2003. http://www.toast-uk.org.uk/xenical_reductil.html
- Utojo Sukaton. 1993. Risiko Obesitas. *Ilmu Penyakit Dalam*. Jakarta. Balai Penerbit FKUI.
- WHO. 1998. *Body Fat Distribution*. Dalam: *The Asia-Pasific Perspective: Redefining Obesity and It's Treatment*.